.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Exploring Biliary Tract Cancer: Top Takeaways From ASCO GI 2025

Shubham Pant, MD, MBBS; Haley Ellis, MD; Amit Mahipal, MD; and Darshil Shah, MD, MPH, examine the evolving landscape of biliary tract cancer management, covering critical aspects from initial prognosis communication through biomarker testing strategies, first-line immunotherapy combinations, and the emergence of HER2-targeted therapies, while highlighting recent clinical trial data and ongoing challenges in optimizing patient outcomes.

EP. 1: Guiding Patients Through Advanced BTC Prognosis and Expectations

February 19th 2025

Panelists discuss how physicians typically communicate survival outcomes and prognosis to patients with newly diagnosed advanced biliary tract cancer (BTC), focusing on setting realistic expectations while maintaining hope.

EP. 2: The Importance of Early Biomarker Testing in Managing Advanced BTC

February 19th 2025

Panelists discuss how comprehensive molecular profiling and biomarker testing are critical for guiding targeted therapy decisions in advanced biliary tract cancer (BTC), citing recent real-world data presented at ASCO GI that demonstrated improved outcomes with matched targeted therapies.